Liberty Defense (DETX) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Niki BioSolutions is the larger company by market cap ($12.8 million vs $10.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DETX | NIKI |
|---|---|---|
| Share price | $1.90 | $4.10 |
| Market cap | $10.80M | $12.79M |
| 1-day change | 0.00% | -5.09% |
| YTD return | — | -59.25% |
| 1-year return | — | -82.07% |
| 5-year return | — | -98.33% |
| EPS (TTM) | $-5.21 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.00 | $24.00 |
| 52-week low | $1.81 | $4.00 |
| Distance from 52-week high | -72.86% | -82.92% |
| Average volume | 21.57K | 157.52K |
| Shares outstanding | 5.68M | 2.94M |
| Employees | — | 1 |
| Sector | Industrials | Industrials |
| Industry | Industrial Machinery/Components | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liberty Defense
DETX stock →Liberty Defense Holdings, Ltd., through its subsidiaries, engages in the development and commercialization of security detection technologies in Canada, the United States, and internationally. The company operates through the HEXWAVE and Contract segments.
Industrials · Industrial Machinery/Components
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
DETX vs NIKI FAQ
Which is bigger, Liberty Defense or Niki BioSolutions?
Niki BioSolutions (NIKI) is larger, with a market capitalization of $12.79M compared with $10.80M for Liberty Defense (DETX).
Are Liberty Defense and Niki BioSolutions in the same industry?
Yes. Both are classified in the Industrial Machinery/Components industry within the Industrials sector.